These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 32007196)

  • 1. CAR T-cell product performance in haematological malignancies before and after marketing authorisation.
    Elsallab M; Levine BL; Wayne AS; Abou-El-Enein M
    Lancet Oncol; 2020 Feb; 21(2):e104-e116. PubMed ID: 32007196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT.
    Hayden PJ; Sirait T; Koster L; Snowden JA; Yakoub-Agha I
    Curr Res Transl Med; 2019 Aug; 67(3):79-88. PubMed ID: 31182380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
    Boyiadzis MM; Dhodapkar MV; Brentjens RJ; Kochenderfer JN; Neelapu SS; Maus MV; Porter DL; Maloney DG; Grupp SA; Mackall CL; June CH; Bishop MR
    J Immunother Cancer; 2018 Dec; 6(1):137. PubMed ID: 30514386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What CAR Will Win the CD19 Race?
    Quintás-Cardama A
    Mol Cancer Ther; 2019 Mar; 18(3):498-506. PubMed ID: 30824581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The promise of CAR T-cell therapy in aggressive B-cell lymphoma.
    Nair R; Neelapu SS
    Best Pract Res Clin Haematol; 2018 Sep; 31(3):293-298. PubMed ID: 30213399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
    Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
    Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in chimeric antigen receptor T cells.
    Beyar-Katz O; Gill S
    Curr Opin Hematol; 2020 Nov; 27(6):368-377. PubMed ID: 32925186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chimeric antigen receptor T-cell therapy for hematological malignancies].
    Nakazawa Y
    Rinsho Ketsueki; 2019; 60(9):1351-1357. PubMed ID: 31597863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC].
    Beauvais D; Bachy E; Baruchel A; Bay JO; Caillot D; Cartron G; Damaj G; Furst S; Le Gouill S; Morschhauser F; Rabian F; Rubio MT; Thieblemont C; Yakoub-Agha I
    Bull Cancer; 2021; 108(7-8):725-729. PubMed ID: 33423776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [How to perform leukapheresis for procurement of the staring material used for commercial CAR T-cell manufacturing: A consensus from experts convened by the SFGM-TC].
    Carnoy S; Beaumont JL; Kanouni T; Parquet N; Beauvais D; Hequet O; Kanold J; Ballot C; Mialou V; Reppel L; Damaj G; Yakoub-Agha I; Chabannon C
    Bull Cancer; 2021 Mar; 108(3):295-303. PubMed ID: 33610284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Summary of US Food and Drug Administration Chimeric Antigen Receptor (CAR) T-Cell Biologics License Application Approvals From a Statistical Perspective.
    Lin X; Lee S; Sharma P; George B; Scott J
    J Clin Oncol; 2022 Oct; 40(30):3501-3509. PubMed ID: 35613410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upsetting the apple CAR-T (chimeric antigen receptor T-cell therapy) - sustainability mandates USA innovation.
    Pantin J; Battiwalla M
    Br J Haematol; 2020 Sep; 190(6):851-853. PubMed ID: 32358811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Reporting data of patients receiving CAR T cell therapy into the EBMT registry: Guidelines of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
    Vasseur A; Karam M; Chaillou D; Colonnese E; Dantin C; Latiere C; Meziane Y; Pereira M; Yakoub-Agha I; Chabannon C; Raus N
    Bull Cancer; 2020 Dec; 107(12S):S178-S184. PubMed ID: 31831153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor T-cell therapy: Foundational science and clinical knowledge for pharmacy practice.
    Dushenkov A; Jungsuwadee P
    J Oncol Pharm Pract; 2019 Jul; 25(5):1217-1225. PubMed ID: 30890066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
    Levin A; Shah NN
    Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy.
    Bouziana S; Bouzianas D
    Crit Rev Oncol Hematol; 2021 Jan; 157():103096. PubMed ID: 33181441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy.
    Byrne M; Oluwole OO; Savani B; Majhail NS; Hill BT; Locke FL
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):e344-e351. PubMed ID: 31279751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Application of CAR-T Cells in Haematological Malignancies.
    Skorka K; Ostapinska K; Malesa A; Giannopoulos K
    Arch Immunol Ther Exp (Warsz); 2020 Nov; 68(6):34. PubMed ID: 33156409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice.
    Bonaldo G; Montanaro N; AlbertoVaccheri ; Motola D
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1225-1234. PubMed ID: 33608749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
    Gauthier J; Turtle CJ
    Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.